Kaiser Health News
The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
by Arthur Allen
Wed, 02 Aug 2023 09:00:00 +0000
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors most likely to suffer from dementia.
Medicare and Medicaid patients will make up 92% of the market for lecanemab, according to Eisai Co., which sells the drug under the brand name Leqembi. In addition to the company’s $26,500 annual price tag for the drug, treatment could cost U.S. taxpayers $82,500 per patient per year, on average, for genetic tests and frequent brain scans, safety monitoring, and other care, according to estimates from the Institute for Clinical and Economic Review, or ICER. The FDA gave the drug full approval July 6. About 1 million Alzheimer’s patients in the U.S. could qualify to use it.
Patients with early Alzheimer’s disease who took lecanemab in a major clinical trial declined an average of five months slower than other subjects over an 18-month period, but many suffered brain swelling and bleeding. Although those side effects usually resolved without obvious harm, they apparently caused three deaths. The great expense of the drug and its treatment raises questions about how it will be paid for, and who will benefit.
“In the history of science, it’s a significant achievement to slightly slow down progression of dementia,” said John Mafi, a researcher and associate professor of medicine at the David Geffen School of Medicine at UCLA. “But the actual practical benefits to patients are very marginal, and there is a real risk and a real cost.”
To qualify for Leqembi, patients must undergo a PET scan that looks for amyloid plaques, the protein clumps that clog the brains of many Alzheimer’s patients. About 1 in 5 patients who took Leqembi in the major clinical test of the drug developed brain hemorrhaging or swelling, a risk that requires those taking the drug to undergo frequent medical checkups and brain scans called MRIs.
In anticipation of additional costs from the Leqembi drug class, the Centers for Medicare & Medicaid Services in 2021 increased monthly premiums for Medicare patients by 15%, and premiums may rise again in 2024 after a slight decline this year.
Such increases can be a significant burden for many of the 62 million Medicare subscribers who live on fixed incomes. “Real people will be affected,” Mafi said. He contributed to a study that estimated lecanemab and related care would cost Medicare $2 billion to $5 billion a year, making it one of the most expensive taxpayer-funded treatments.
In its analysis, ICER suggested that Leqembi could be cost-effective at an annual price of $8,900 to $21,500. In an interview, David Rind, ICER’s chief medical officer, said $10,000 to $15,000 a year would be reasonable. “Above that range doesn’t seem like a good place,” he said.
Whatever its price, patients may be delayed getting access to Leqembi because of the relative shortage of specialists capable of managing the drug, which will require genetic and neuropsychological testing as well as the PET scan to confirm a patient’s eligibility. A similar drug, Eli Lilly’s donanemab, is likely to win FDA approval this year.
Already there are long waits for the testing needed to assess dementia, Mafi said, noting that one of his patients with mild cognitive impairment had to wait eight months for an evaluation.
Such testing is not readily at hand because of the paucity of effective treatment for Alzheimer’s, which has helped to make geriatrics a relatively unappealing specialty. The United States has about a third as many dementia specialists per capita as Germany, and about half as many as Italy.
“Time is of the essence” for the neuropsychological testing, Mafi said, because once a patient’s cognitive ability declines below a certain threshold, they become ineligible for treatment with the drug, which was tested only in patients in the earliest stages of the disease.
Mafi’s study estimates that patients without supplemental Medicare coverage will have to pay about $6,600 out-of-pocket for each year of treatment. That could put it out of reach for many of the 1 in 7 “dual eligible” Medicare beneficiaries whose income is low enough to simultaneously qualify them for state Medicaid programs. Those programs are responsible for about 20% of physician bills for drug infusions, but they don’t always cover the full amount.
Some practitioners, such as cancer centers, cover their Medicaid losses by receiving higher rates for privately insured patients. But since almost all lecanemab patients are likely to be on government insurance, that “cross-subsidization” is less of an option, said Soeren Mattke, director of the Center for Improving Chronic Illness Care at the University of Southern California.
This poses a serious health equity issue because “dual eligibles are low-income patients with limited opportunities and education, and at higher risk of chronic illnesses including dementia,” Mattke said in an interview. Yet many doctors may not be willing to treat them, he said. “The idea of denying access to this group is just appalling.”
Eisai spokesperson Libby Holman said the company was reaching out to specialists and primary care physicians to make them aware of the drug, and that reimbursement options were improving. Eisai will provide the drug at no cost to patients in financial need, she said, and its “patient navigators” can help lock down insurance coverage.
“A lot of clinicians are excited about the drug, and patients are hearing about it,” said David Moss, chief financial officer of INmune Bio, a company that has another Alzheimer’s drug in development. “It’s a money center for infusion centers and MRI operators. It provides reasons for patients to come into the office, which is a billing thing.”
Outstanding doubts about Leqembi and related drugs have given urgency to efforts to monitor patient experiences. CMS is requiring Leqembi patients to be entered into a registry that tracks their outcomes. The agency has established a registry, but the Alzheimer’s Association, the leading advocacy group for dementia patients, is funding its own database to track those being treated, offering physician practices $2,500 to join it and up to $300 per patient visit.
In a letter to CMS on July 27, a group of policy experts said CMS should ensure that any and all Leqembi registries create and share data detailed enough for researchers and FDA safety teams to obtain a clear picture of the drug’s real-world profile.
The anti-amyloid drugs like lecanemab have created a polarized environment in medicine between those who think the drugs are a dangerous waste of money and those who believe they are a brilliant first step to a cure, said ICER’s Rind, who thinks lecanemab has modest benefits.
“People are as dug in on this as almost anything I’ve ever seen in medicine,” he said. “I don’t think it’s healthy.”
By: Arthur Allen
Title: The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
Sourced From: kffhealthnews.org/news/article/the-real-costs-of-the-new-alzheimers-drug-most-of-which-will-fall-to-taxpayers/
Published Date: Wed, 02 Aug 2023 09:00:00 +0000
Did you miss our previous article…
https://www.biloxinewsevents.com/black-women-weigh-emerging-risks-of-creamy-crack-hair-straighteners/
Kaiser Health News
Election Outcome Could Bring Big Changes to Medicare
SUMMARY: During the campaign, both Donald Trump and Kamala Harris are positioning themselves as defenders of Medicare, each blaming the other for potential cuts to the program. The election could significantly impact Medicare’s future, especially with more beneficiaries opting for Medicare Advantage plans run by private insurers, a trend that could escalate under a Trump administration. Critics warn that increased privatization would limit care options and raise costs, while supporters argue these plans provide better benefits. Polls indicate that a candidate’s stance on Medicare heavily influences voter decisions, highlighting the program’s importance in the upcoming election.
The post Election Outcome Could Bring Big Changes to Medicare appeared first on kffhealthnews.org
Kaiser Health News
What’s at Stake: A Pivotal Election for Six Big Health Issues
SUMMARY: In the election campaign’s final days, Vice President Kamala Harris and former President Donald Trump clash over health care, including issues of abortion access and the Affordable Care Act (ACA). Harris aims to preserve ACA subsidies and protect health care rights, while Trump’s campaign lacks clarity on health plans, suggesting significant cuts. The future of Medicaid, drug prices, and transgender health care also hinges on the election outcome. Trump’s proposals could roll back protections for these groups, contrasting with Harris’ promises to uphold existing health care rights and enhance drug pricing negotiations, setting stark differences for voters.
The post What’s at Stake: A Pivotal Election for Six Big Health Issues appeared first on kffhealthnews.org
Kaiser Health News
Trump quiere que Harris pague un precio político por ofrecer salud a inmigrantes sin papeles
SUMMARY: María Sánchez, una inmigrante de 87 años de México, vive sin papeles en Illinois y carecía de seguro médico durante años, a pesar de haber trabajado y pagado impuestos. A los 65, no pudo inscribirse en Medicare y evitó atención hasta caer enferma. En 2020, Illinois lanzó un programa que cubre a mayores indocumentados, permitiendo a María acceder a atención médica que le salvó la vida. Esta iniciativa se enmarca en un movimiento más amplio en estados demócratas para proporcionar seguro a inmigrantes. Sin embargo, enfrenta críticas republicanas y desafíos económicos, dado el creciente costo del programa en Illinois.
The post Trump quiere que Harris pague un precio político por ofrecer salud a inmigrantes sin papeles appeared first on kffhealthnews.org
-
Kaiser Health News7 days ago
Vance Wrongly Blames Rural Hospital Closures on Immigrants in the Country Illegally
-
News from the South - Georgia News Feed6 days ago
Co-defendant takes plea deal in YSL RICO trial | FOX 5 News
-
Mississippi News Video6 days ago
Free Clinic of Meridian Celebrates 10 Years
-
Our Mississippi Home7 days ago
A New Deep Sea Remotely Operated Vehicle Coming to USM
-
News from the South - Arkansas News Feed6 days ago
Buc-ee’s set to open second Arkansas location
-
News from the South - North Carolina News Feed6 days ago
FBI arrests NC man known as 'AK Guru' who is accused of selling hundreds of machine guns
-
News from the South - Alabama News Feed3 days ago
“There is a man here trying to use your ID” Suspect caught in Elberta using stolen ID at victims wor
-
News from the South - Texas News Feed3 days ago
Former HISD employees accused in teacher cheating scheme try to avoid cameras at first court hearing